WADA's 2027 Prohibited List Writes 'Peptides' Into Its Catch-All Ban
Published: September 30, 2026 · 3 min read · By Grey Peptides News Desk · ✓ Sourced
WADA's 2027 Prohibited List, which takes effect on January 1, 2027, adds the word 'peptides' to the examples in S0, its ban on substances no health authority has approved for human use. BPC-157 stays named. WADA's own notes say the change is for clarity: many unapproved peptides were already covered, by S0 or by other sections such as S2 and S4, and a peptide the List does not name can still be prohibited.
What changed in S0
S0 covers any pharmacological substance that no other section of the List addresses and that has no current approval from any government health authority for human therapeutic use. It applies at all times, in and out of competition, and everything in it is a Specified Substance. The 2026 text gave drugs still in development, discontinued drugs, designer drugs and veterinary-only substances as examples. The 2027 text adds peptides to that list. The named examples are otherwise unchanged: BPC-157 remains the only peptide named, beside DNP, two ryanodine receptor stabilizers and two troponin activators.
WADA's summary of the changes explains why. Many peptides that are not approved for human use meet the World Anti-Doping Code's criteria for the List, and they fall under S0 or under other sections such as S2 (peptide hormones and growth factors) or S4 (hormone and metabolic modulators). A peptide that is not named may still be prohibited and may still be harmful, the agency says, and peptides are now named as examples so that nobody reads their absence as permission.
What it means for the peptides on this site
The rule did not widen; its wording caught up. Every entry in our encyclopedia carries its status for both 2026 and 2027 in its Legal table, and the counts barely move: 73 entries are prohibited under a specific section in both years, such as TB-500 under S2.3 and MOTS-c under S4.4.1, and 114 more fall under the S0 catch-all by our reading of the definition. What the new wording removes is the argument that an unnamed research peptide is allowed. It never was, if no health authority has approved it for human use.
The other changes near peptides
Two research compounds, SLU-PP-332 and SLU-PP-915, are now named in S4 as metabolic modulators acting on oxidative metabolism; neither is a peptide. S4 also adds imlunestrant and seladelpar, and S5 adds eplerenone and finerenone. The monitoring program, which tracks substances WADA is watching but does not prohibit, drops dermorphin and its analogues, an opioid peptide, along with codeine, hydrocodone, and fentanyl and tramadol out of competition, because enough data have been collected.
What it does not change
Approved medicines are outside S0 by definition; whether one is prohibited depends on the other sections, and GLP-1 medicines such as semaglutide are not on the 2027 List. The change also says nothing about legality outside sport. S0 is an anti-doping rule for athletes subject to the Code, not a statement about what may be sold or prescribed.
Related on Grey Peptides
Each tracked peptide's FDA, compounding and WADA status, dated at source. BPC-157
The one peptide S0 names, and what its evidence actually shows. Compound explorer
Filter every encyclopedia entry by WADA status and evidence grade.
List text dated August 26, 2026; explanatory notes dated August 17, 2026; in force January 1, 2027. Both read in full September 27, 2026.